Mp15-05 Prognostic Value of Tumor-Agnostic Circulating Tumor Dna Testing in Muscle-Invasive Bladder Cancer

You have accessJournal of UrologyBladder Cancer: Basic Research p<0.05; Figure 1). Lastly, dynamic changes in ctDNA status between baseline and four months later were significantly associated with patient outcomes (p=0.045; Figure 2). CONCLUSIONS: Longitudinal ctDNA analysis using a tumor-agnostic approach is a potential tool for monitoring MIBC patients after RC. The implementation of this testing in the clinical setting could improve disease management and patients' outcomes. Download PPTDownload PPT Source of Funding: Instituto de Salud Carlos III (ISCIII): project references number PI20/00409 © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e230 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Raquel Carrasco More articles by this author Mercedes Ingelmo-Torres More articles by this author Ramón Trullas More articles by this author Fiorella L. Roldán More articles by this author Leonardo Rodríguez-Carunchio More articles by this author Marcel Figueras More articles by this author Claudia Mercader More articles by this author Bernat Padullés More articles by this author Jasmine L. Olegario More articles by this author Joan Sureda More articles by this author Antonio Alcaraz More articles by this author Laura Izquierdo More articles by this author Lourdes Mengual More articles by this author Expand All Advertisement PDF downloadLoading ...